Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1980 2
1981 1
1985 1
1986 1
1987 3
1989 3
1990 1
1992 2
1993 2
1994 4
1995 4
1996 5
1997 5
1998 4
1999 2
2000 4
2001 4
2002 9
2003 8
2004 9
2005 9
2006 7
2007 7
2008 10
2009 10
2010 6
2011 1
2012 15
2013 11
2014 9
2015 11
2016 6
2017 11
2018 16
2019 20
2020 20
2021 32
2022 23
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF; PBC Consortia; Canadian PBC Consortium; Chinese PBC Consortium; Italian PBC Study Group; Japan-PBC-GWAS Consortium; US PBC Consortium; UK-PBC Consortium. Cordell HJ, et al. J Hepatol. 2021 Sep;75(3):572-581. doi: 10.1016/j.jhep.2021.04.055. Epub 2021 May 23. J Hepatol. 2021. PMID: 34033851 Free PMC article.
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG) collaborators(‡). Pape S, et al. J Hepatol. 2022 Apr;76(4):841-849. doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20. J Hepatol. 2022. PMID: 35066089 Free article.
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Vitale A, et al. Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21. Gut. 2023. PMID: 34933916
Diagnostic approach to autoimmune hepatitis.
Muratori P, Lenzi M, Cassani F, Lalanne C, Muratori L. Muratori P, et al. Among authors: muratori l. Expert Rev Clin Immunol. 2017 Aug;13(8):769-779. doi: 10.1080/1744666X.2017.1327355. Epub 2017 May 17. Expert Rev Clin Immunol. 2017. PMID: 28480763 Review.
HCV and autoimmunity.
Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. Ferri S, et al. Among authors: muratori l. Curr Pharm Des. 2008;14(17):1678-85. doi: 10.2174/138161208784746824. Curr Pharm Des. 2008. PMID: 18673191 Review.
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis.
Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DE, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch KA; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium; Japan PBC-GWAS Consortium; Carbone M, Cardamone G, Duga S, Gershwin ME, Seldin MF, Invernizzi P. Asselta R, et al. Gastroenterology. 2021 Jun;160(7):2483-2495.e26. doi: 10.1053/j.gastro.2021.02.061. Epub 2021 Mar 4. Gastroenterology. 2021. PMID: 33675743 Free PMC article.
Antinuclear antibodies in COVID 19.
Muratori P, Lenzi M, Muratori L, Granito A. Muratori P, et al. Among authors: muratori l. Clin Transl Sci. 2021 Sep;14(5):1627-1628. doi: 10.1111/cts.13026. Epub 2021 May 1. Clin Transl Sci. 2021. PMID: 33932091 Free PMC article. No abstract available.
An MDS Evidence-Based Review on Treatments for Huntington's Disease.
Fritz NE, Busse M, Muratori LM, Rao AK, Kloos A, Kegelmeyer D, Quinn L. Fritz NE, et al. Among authors: muratori lm. Mov Disord. 2022 Jul;37(7):1566-1567. doi: 10.1002/mds.29059. Mov Disord. 2022. PMID: 35856726 Review. No abstract available.
287 results